CJC-1295 DAC - 2mg

CJC-1295 DAC has demonstrated outstanding results as releasing analog (GHRH) growth hormone. In addition to the ability to increase the secretion of IGF-I and growth hormone, it has been able to do so in significant amounts.

Research studies, conducted recently, show that CJC-1295 stimulates IGF-1 and HGH secretion without increasing prolactin. Consequently, there is an increase in protein synthesis and significant fat loss.

The first clinical research studies made for the CJC-1295 were carried out in the mid-2000s. The peptide’s goal was to treat deposits of fat in Aids patients. The hypothesis was based on the fact that high levels of exogenous HGH promote fat loss. This clinical research was successful for the majority of the test subjects.

Studies have also found that through the combination of GHRP with CJC 1295 DAC, a significant increase in the release of GH and IGF-1 occurs without the increase in the levels of prolactin.
Some good examples of a GHRH are Ipamorelin or GHRP-2.
CJC 1295 DAC is an exceptional peptide and known as the finest of the hGH secretagogues. Its portion of DAC (Drug Affinity Complex) increases the half-life through the binding with serum albumin and also protects it from degradation.

CJC-1295 DAC and CJC-1295 (known by others as Modified GRF 1-29) are both great growth hormone-releasing hormones and their action in the human body are identical. There are, however, differences between these two peptides regarding their half-life. Whilst modified GRF 1-20 has quite a short action half-life (30 minutes), the CJC-1295 DAC can last up to eight days and many scientists have reported that the shorter half-life of the modified GRF 1-29 is far more natural as it produces a short pulse of the Human Growth Hormone.

.

REFERENCES:

https://pubmed.ncbi.nlm.nih.gov/1752922

https://pubmed.ncbi.nlm.nih.gov/17018654

https://pubmed.ncbi.nlm.nih.gov/16352683

https://journals.physiology.org/doi/full/10.1152/ajpendo.00201.2006